News

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in a fireside chat during the Jefferies Virtual

Regulatory News:

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”)

Regulatory News:

NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities

Regulatory News:

The Combined Ordinary and Extraordinary General Meeting of Transgene’s (Paris:TNG) shareholders was held today (May 26, 2021) at 10:00 a.m. at the Company's headquarters (400

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at the Jefferies Virtual

Regulatory News:

NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, announced today that the Company submitted a supplemental New Drug Application (“sNDA”) for BIJUVA (estradiol

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial Officer

TherapeuticsMD, Inc. (NASDAQ: TXMD), has been awarded a Top Workplaces 2021 honor by The Sun Sentinel. The list is based solely on employee feedback gathered through a third-party survey

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Friday, June 4^th

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) announced today that a supportive interim analysis of its AURORA 2 continuation study will be presented at the

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that four abstracts featuring data from clinical studies evaluating Rubraca and/or lucitanib and one abstract on real world data of PARP

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210519005957/en/

Please replace the release dated May 19, 2021 with

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced publication of three abstracts on neratinib for the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has filed a prospectus supplement with the U.S. Securities and Exchange Commission (“SEC”), under which it may offer and sell, from time

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Savara management will be presenting at the Oppenheimer Rare &amp

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that on May 11, 2021, the Compensation Committee of the Company’s Board

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate in two upcoming investor conferences:

• 
  RBC

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today reported financial results for the first quarter ending March 31, 2021 and

Regulatory News:

NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities

Regulatory News:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511006169/en/

NANOBIOTIX (Euronext : NANO – NASDAQ: NBTX), a

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today, in recognition of World Lupus Day, affirmed its commitment to increasing access to equitable healthcare for

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today announced that The Lancet, an international, peer-reviewed medical journal, published the results of the

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2021. Unless otherwise stated, all comparisons are for the

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today issued its financial results for the first quarter ended March 31, 2021. Amounts, unless specified